Paper Details

  1. Home
  2. Paper Details

Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.

Author: González FernándezCarlos M, Gratacós MasmitjàJordi, Gómez CastroSusana, Rebollo LasernaFrancisco José

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Psoriatic arthritis (PsA) is treated with a variety of approaches, including lifestyle changes, pain relief medications, and targeted drugs that suppress the immune system. This review will summarize the latest research on the effectiveness of tofacitinib, a medication that blocks a specific enzyme, for treating PsA, focusing on how well it works for joint problems, spine problems, inflammation in tendons, and inflammation in fingers and toes.
Paper Details　
Original Abstract of the Article :
Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors. This systematic review aimed to provide complete a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12325-020-01585-7

データ提供：米国国立医学図書館（NLM）

Tofacitinib: A Potential Oasis for Psoriatic Arthritis

This study dives deep into the complex world of [rheumatology] and [immunology], focusing on the use of tofacitinib, a [Janus kinase inhibitor], in the treatment of psoriatic arthritis (PsA). The study systematically reviews the current literature on tofacitinib's efficacy in treating PsA, including its impact on various aspects of the disease, such as peripheral arthritis, axial disease, enthesitis, and dactylitis.

Tofacitinib: A New Weapon in the Fight Against Psoriatic Arthritis

Tofacitinib holds great promise as a new therapeutic option for PsA. Just as a camel relies on its strong legs to navigate harsh deserts, tofacitinib can provide much-needed relief for those battling the debilitating effects of PsA.

Implications for Psoriatic Arthritis Management

This review provides a comprehensive overview of the potential benefits of tofacitinib for PsA, highlighting its efficacy in treating various aspects of the disease.

Dr. Camel's Conclusion

This research underscores the importance of new therapeutic strategies for treating PsA. Just as a camel's perseverance helps it overcome desert challenges, tofacitinib offers a new path to relief for PsA patients.

Date :
  1. Date Completed 2021-04-14
  2. Date Revised 2021-07-19
Further Info :

Pubmed ID

33331985

DOI: Digital Object Identifier

10.1007/s12325-020-01585-7

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.